Clozapine: An effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital

CNS Spectrums

Volumn 19, Issue 5, 2013, Pages 391-402

  Brown, Darcy ^a   Larkin, Fintan ^b   Sengupta, Samrat ^b   Romero Ureclay, Jose L ^b   Ross, Callum C ^b   Gupta, Nitin ^c   Vinestock, Morris ^b   Das, Mrigendra ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b BROADMOOR HOSPITAL   (United Kingdom)

^c GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Antipsychotic; antisocial; clozapine; personality disorder; psychopath; violence

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; DIAZEPAM; DULOXETINE; FLUOXETINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; METHADONE; MIRTAZAPINE; NORCLOZAPINE; PREGABALIN; QUETIAPINE; SERTRALINE; TOPIRAMATE; TRIHEXYPHENIDYL; VALPROIC ACID; VENLAFAXINE; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT;

ADULT; AFFECTIVE DYSREGULATION; AGGRESSION; ANGER; ANTISOCIAL PERSONALITY DISORDER; ANXIETY; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE PERCEPTUAL SYMPTOM; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DROWSINESS; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HIGH SECURITY HOSPITAL; HOSPITAL; HUMAN; HYPERSALIVATION; IMPULSIVE BEHAVIORAL DYSCONTROL; INCIDENCE; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MENTAL INSTABILITY; METABOLIC PARAMETERS; MIDDLE AGED; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOPATHY; RISK REDUCTION; SIDE EFFECT; SLURRED SPEECH; SYMPTOM; TACHYCARDIA; TOTAL CHOLESTEROL HIGH DENSITY LIPID RATIO; TREATMENT DURATION; UNITED KINGDOM; VERBAL HOSTILITY; VIOLENCE; WEIGHT GAIN; COHORT ANALYSIS; EMOTIONAL DISORDER; IMPULSIVENESS; MENTAL HOSPITAL; METABOLISM; ORGANIZATION AND MANAGEMENT; PREVENTION AND CONTROL; PSYCHOLOGY; RETROSPECTIVE STUDY; SLEEP STAGE; TREATMENT OUTCOME;

ADULT; AFFECTIVE SYMPTOMS; AGGRESSION; ANTIPSYCHOTIC AGENTS; ANTISOCIAL PERSONALITY DISORDER; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CLOZAPINE; COHORT STUDIES; HOSPITALS, PSYCHIATRIC; HUMANS; IMPULSIVE BEHAVIOR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SECURITY MEASURES; SLEEP STAGES; TREATMENT OUTCOME; UNITED KINGDOM; VIOLENCE;

EID: 84914148447     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852914000157     Document Type: Article

References (81)

1. Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010; 71(1): 14-25.
2. Lieb K, Völlm B, Rücker G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010; 196(1): 4-12.
3. Stoffers JBA, Völlm G, Rücker A, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010; (6): CD005653.
4. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2006; 67(7): 1042-1046.
5. Hilger E, Barnas C, Kasper S. Quetiapine in the treatment of borderline personality disorder. World J Biol Psychiatry. 2003; 4(1): 42-44.
6. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry. 2005; 66(10): 1298-1303.
7. Nickel M, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006; 16 3 (5): 833-838.
8. Bellino S, Bozzatello P, Rinaldi C, Bogetto F. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress Res Treat. 2011; 2011: 680194.
9. Grootens KP, Verkes RJ. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry. 2005; 38(01): 20-23.
10. Bogenschutz MP, Nurnberg G. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004; 65(1): 104-109.
11. Linehan MM, McDavid JD, Brown MZ, Sayrs JH, Gallop RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008; 69(6): 999-1005.
12. Schulz CS, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and co-morbid dysthymia. Biol Psychiatry. 1999; 46(10): 1429-1435.
13. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004; 65(7): 903-907.
14. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001; 62(11): 849-854.
15. Keshavan M, Shad M, Soloff P, Schooler N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res. 2004; 71(1): 97-101.
16. Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003; 64(6): 628-634.
17. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 2002; 63(3): 241-244.
18. Vauquelin G, Bostoen S, Vanderheyden P, Seeman P. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol. 2012; 385(4): 337-372.
19. Fakra E, Azorin J. Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother. 2012; 13(3): 1923-1935.
20. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001; 158(4): 518-526.
21. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45(9): 789-796.
22. Meltzer, Herbert Y. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin. 1997; 14(1): 1-20.
23. Chengappa KN, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry. 1999; 60(7): 477-484.
24. Vohra AK. Treatment of severe borderline personality disorder with clozapine. Indian J Psychiatry. 2010; 52(3): 267-269.
25. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998; 59(3): 103-107.
26. Swinton M. Clozapine in severe borderline personality disorder. The Journal of Forensic Psychiatry. 2001; 12(3): 580-591.
27. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry. 1993; 34(6): 402-405.
28. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law. 1995; 23(4): 607-611.
29. Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol. 2012; 15(9): 1351-1371.
30. Chengappa KNR, Vasile J, Levine J, et al. Clozapine: its impact on aggressive behaviour among patients in a state psychiatric hospital. Schizophr Res. 2002; 53(1-2): 1-6.
31. Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv. 2001; 52(11): 1510-1514.
32. Dalal B, Larkin E, Leese M, Taylor PJ. Clozapine treatment of longstanding schizophrenia and serious violence: a two-year follow-up study of the first 50 patients treated with clozapine in Rampton high security hospital. Crim Behav Ment Health. 1999; 9(2): 168-178.
33. Rabinowitz J, Avnon M, Rosenberg V. Effect of clozapine on physical and verbal aggression. Schizophr Res. 1996; 22(3): 249-255.
34. Ratey JJ, Leveroni C, Kilmer D, Gutheil C. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry. 1993; 54(6): 219-223.
35. Volavka J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychiatry. 1999; 60(Suppl 12): 43-46.
36. Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006; 63(6): 622-629.
37. Hare RD. Manual for the Revised Psychopathy Checklist (1st ed.). 1991. Toronto, ON, Canada: Multi-Health Systems. URL for other refs: http://scholar.google.co.uk/scholar?hl5en&q5hare1checklist& btnG5&as-sdt51%2C5&as-sdtp5
38. st ed). Toronto, ON, Canada.
39. Guy W. The Clinical Global Impression Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rev ed. Rockville, MD: U.S. Department of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch; 1976:218-222.
40. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry. 1993; 34(6): 402-405.
41. Binks CA, Fenton M, McCarthy L, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2006; (1): CD005652.
42. Soloff PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioural dysregulation. Bull Menninger Clin. 1997; 62(2): 195-214.
43. Webster C, Douglas K, Eaves D, Hart S. HCR-20: Assessing Risk for Violence. Version 2; 1992. Burnaby, BC, Canada: Mental Health, Law and Policy Institute, Simon Fraser University.
44. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992; 50.
45. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
46. Glazer GM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry. 1998; 59(Suppl 3): 8-14.
47. Spina E, Avenoso A, Facciolà G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl). 2000; 14 8 (1): 83-89.
48. Humbert-Claude M, Davenas E, Gbahou F, Vincent L, Arrang JM. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl). 2012; 220(1): 225-241.
49. Stahl SM. Psychopharmacology of Antipsychotics. London: Martin Dunitz; 1999.
50. Harrison AA, Everitt BJ, Robbins TW. Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology (Berl). 1997; 133(4): 329-342.
51. 2L receptor-and age-related reduction in offensive aggression. Neuroreport. 2001; 12(5): 1035-1038.
52. Wade TR, Wit HD, Richards JB. Effects of dopaminergic drugs on delayed reward as a measure of impulsive behaviour in rats. Psychopharmacology (Berl). 2000; 150(1): 90-101.
53. Chotai J, Kullgren J, Åsberg M. CSF monoamine metabolites in relation to the diagnostic interview for borderline patients (DIB). Neuropsychobiology. 1998; 38(4): 207-212.
54. Coccaro EF, Silk KR, ed. Neurotransmitter function in personality disorders. In: Biology of Personality Disorders. Washington, DC: American Psychiatric Press; 1998: 1-25.
55. Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004; 29(6): 1029-1039.
56. Adams DB. Brain mechanisms for offence, defence, and submission. Behav Brain Sci. 1979; 2(2): 201-213.
57. Berman ME, Tracy JI, Coccaro EF. The serotonin hypothesis of aggression revisited. Clin Psychol Rev. 1997; 17 (6): 651-665.
58. Brown GL. Aggression, suicide, and serotonin: relationships of CSF amine metabolites. Am J Psychiatry. 1982; 139(6): 741-746.
59. 1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur J Pharmacol. 2005; 526(1-3): 125-139.
60. Gowin JL, Swann AC, Moeller FG, Lane SD. Zolmitriptan and human aggression: interaction with alcohol. Psychopharmacology (Berl). 2010; 210(4): 521-531.
61. Miczek KA, Fish EW, Joseph F, De Almeida RM. Social and neural determinants of aggressive behaviour: pharmacotherapeutic targets at serotonin, dopamine and g-aminobutyric acid systems. Psychopharmacology (Berl). 2002; 163(3): 434-458.
62. Moss HB, Yao JK, Panzak GL. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol Psychiatry. 1990; 28(4): 325-338.
63. Constantino JN, Morris JA, Murphy DL. CSF 5-HIAA and family history of antisocial personality disorder in newborns. Am J Psychiatry. 1997; 154(2): 1771-1773.
64. Krakowski M. Violence and serotonin: influence of impulse control, affect regulation, and social functioning. J Neuropsychiatry Clin Neurosci. 2003; 15(3): 294-305.
65. Umukoro S, Aladeokin AC, Eduviere AT. Aggressive behavior: a comprehensive review of its neurochemical mechanisms and management. Aggression and Violent Behavior. 2012; 18 (2): 195-203.
66. Paris P. Antisocial and borderline personality disorders: two separate diagnoses or two aspects of the same psychopathology? Compr Psychiatry. 1997; 38(4): 237-242.
67. Bateman AW, Tyrer P. Psychological treatment for personality disorders. Advances in Psychiatric Treatment. 2004; 10(5): 378-388.
68. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs. 2008; 22(8): 671-692.
69. Nelson KJ, Schulz CS. Treatment advances in borderline personality disorder. Psychiatric Annals. 2012; 42(2): 59-64.
70. Dolan M. Psychopathic personality in young people. Advances in Psychiatric Treatment. 2004; 10(6): 466-473.
71. Hare RD. Psychopathy, affect and behaviour. In: Cooke DJ, Forth AE, Hare RD, eds. Psychopathy: Theory, Research and Implications for Society. Dordrecht, the Netherlands: Springer; 1998: 105-137.
72. Salekin RT, Rogers R, Sewell KW. A review and meta-analysis of the Psychopathy Checklist and Psychopathy Checklist-Revised: predictive validity of dangerousness. Clinical Psychology: Science and Practice. 1996; 3(3): 203-215.
73. Buckholtz JW, Treadway MT, Cowan RL, et al. Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat Neurosci. 2010; 13(4): 419-421.
74. Dolan MC, Anderson IM. The relationship between serotonergic function and the Psychopathy Checklist: Screening Version. J Psychopharmacol. 2003; 17 (2): 216-222.
75. Soderstrom H, Blennow K, Sjodin AK, Forsman A. New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J Neurol Neurosurg Psychiatry. 2003; 74 (7): 918-921.
76. Barkataki I, Kumar V, Das M, Taylor P, Sharma T. Volumetric structural brain abnormalities in men with schizophrenia or antisocial personality disorder. Behav Brain Res. 2006; 16 9 (2): 239-247.
77. Kumari V, Das M, Taylor PJ, et al. Neural and behavioural responses to threat in men with a history of serious violence and schizophrenia or antisocial personality disorder. Schizoph Res. 2009; 110(1-3): 47-58.
78. Yang Y, Raine R. Prefrontal structural and functional brain imaging findings in antisocial, violent, and psychopathic individuals: a meta-analysis. Psychiatry Res. 2009; 174 (2): 81-88.
79. Chopra HD, Beatson JA. Psychotic symptoms in borderline personality disorder. Am J Psychiatry. 1986; 14 3 (12): 1605-1607.
80. Kendal T, Pilling S, Tyrer P, et al. Guidelines: Borderline and Antisocial Personality Disorders: Summary of NICE Guidance. BMJ. 2009; 338(7689): 293-295.
81. Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr Res. 1999; 35(Suppl): S23-S33.